TMDX— AI Stock Forecast & Price Targets
Published 7/1/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live TMDX price forecast →
TMDX's fundamental strength in organ preservation technology remains compelling with robust revenue growth (30.24% Y/Y TTM) and high ROE (45.22%), but severe negative technical momentum and elevated debt levels create significant near-term risk. The stock trades at a steep discount to its 52-week high ($67.29 vs $156), yet persistent short interest (23.02%) and bearish forecast bands suggest limited upside without catalysts.
Wait for earnings (July 30) as a binary event; if price holds above $65, consider small accumulation at $67-$68 with stop-loss below $62. Invalidation: break below $60.10 (52W low).
Focus on OCS adoption metrics and reimbursement policy changes as catalysts. Target range $90-$100 over 6 months if technicals improve; otherwise, hold for longer-term potential with base target at $80.
Terminal thesis: TMDX could become a dominant player in organ transplantation with recurring revenue from logistics services. Structural risk is regulatory approval timelines and competition from emerging players in transplant tech.
Revenue growth remains strong at 30.24% Y/Y TTM, driven by OCS platform adoption across organ types (Lung, Heart, Liver). Gross margins are healthy at 58.76%, but net margins have compressed to 27.04% due to capital intensity and debt servicing costs. Balance sheet shows high leverage with Debt/Equity of 1.75, though cash reserves ($13.36/sh) provide cushion. Free cash flow is positive at $108.8M annually but has been volatile (Q2 2026: -$12.1M), indicating capital allocation challenges. The company's high ROE (45.22%) and strong operational metrics support long-term potential, but debt overhang creates execution risk if interest rates rise.
The chart shows deep negative momentum with price below both SMA20 (-8.75%) and SMA50 (-15.54%), indicating severe bearish sentiment. Support is near $60-$65 (52W low: $60.10), while resistance at $95 (base target) remains untested. The Kronos AI forecast band shows a narrow range between $71.41 and $90.97, suggesting limited upside potential without a clear catalyst. Short interest (23.02%) amplifies volatility, and the RSI of 38 indicates neutral momentum but with downward pressure from recent declines.
Recent news highlights TMDX's strong growth profile (30% revenue growth) and strategic positioning in organ preservation technology, but also underscores risks: insider sales ($722K sale), high short interest (23.02%), and a 45% stock drop YTD. Stifel's Hold rating with $80 target provides some analyst validation, yet the stock remains significantly below its 52-week high ($156) despite positive operational metrics. The OCS platform's potential to extend organ viability is a key growth driver but faces regulatory uncertainty.
- OCS platform expansion across multiple organ types (Lung, Heart, Liver) driving 30% revenue growth Y/Y
- National OCS program logistics services creating recurring revenue streams
- High debt levels (Debt/Equity: 1.75) increasing execution risk if interest rates rise
- Regulatory uncertainty around reimbursement policies affecting OCS utilization rates
- Persistent negative technical momentum preventing price recovery without catalysts
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord